LTFS
EIDX

Ladenburg Thalmann Financial Services’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-300
Closed -$7K – 5512
2019
Q1 		$7K Hold
300
– – ﹤0.01% 4561
2018
Q4 		$4K Hold
300
– – ﹤0.01% 4716
2018
Q3 		$3K Buy
+300
New +$4.93K ﹤0.01% 4825

Other funds holding EIDX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Ladenburg Thalmann Financial Services's EIDX Position: Q2 2019 in Review

Ladenburg Thalmann Financial Services sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q2 2019, closing a stake of 300 shares — an estimated $7K sold.

Ladenburg Thalmann Financial Services first reported a position in EIDX in Q3 2018 and held it in 3 quarters. The position peaked at $7K in Q1 2019. 78 funds tracked by Wall St. Rank hold EIDX as of Q2 2019.

  • Ladenburg Thalmann Financial Services reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Ladenburg Thalmann Financial Services sold 300 Eidos Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $7K.
  • Ladenburg Thalmann Financial Services first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2018 and held it in 3 quarters.
  • Ladenburg Thalmann Financial Services's Eidos Therapeutics, Inc. Common Stock position peaked at $7K in Q1 2019.
  • 78 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q2 2019, filed 15 Aug 2019.